Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature
Open Access
- 30 March 2017
- journal article
- review article
- Published by Wiley in Clinical Case Reports
- Vol. 5 (5) , 664-670
Abstract
Key Clinical Message: Acquired von Willebrand syndrome may be related to plasma cell dyscrasia and can cause severe bleeding complications. Treatment, for example, with intravenous immunoglobulins may be indicated in selected cases. Physicians treating plasma cell dyscrasia have to be aware of bleeding complications in these patients, and clarification is necessary.Keywords
This publication has 38 references indexed in Scilit:
- Diagnosis and treatment of acquired von Willebrand syndromeThrombosis Research, 2012
- Pathophysiology of acquired von Willebrand disease: a concise reviewEuropean Journal of Haematology, 2011
- Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndromeBlood Coagulation & Fibrinolysis, 2011
- Acquired Factor VIII and von Willebrand Factor (aFVIII/VWF) Deficiency and Hypothyroidism in a Case With HypopituitarismClinical and Applied Thrombosis/Hemostasis, 2008
- Frequency of acquired van Willebrand’s disease in children with congenital heart disease.Acta Cardiologica, 2007
- Bleeding and Thrombosis Risks in Plasma Cell DyscrasiasHematology-American Society Hematology Education Program, 2007
- The Paradox of Platelet Activation and Impaired Function: Platelet-von Willebrand Factor Interactions, and the Etiology of Thrombotic and Hemorrhagic Manifestations in Essential Thrombocythemia and Polycythemia VeraSeminars in Thrombosis and Hemostasis, 2006
- Acquired von Willebrand syndrome: Features and managementAmerican Journal of Hematology, 2006
- Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and managementBest Practice & Research Clinical Haematology, 2001
- Acquired von Willebrand Syndrome in Systemic Lupus ErythematodesClinical and Applied Thrombosis/Hemostasis, 2001